Winthrop, K. L., Citera, G., Gold, D., Henrohn, D., Connell, C. A., Shapiro, A. B., . . . Schulze-Koops, H. (2021). Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Ann Rheum Dis.
Chicago-stil citatWinthrop, Kevin L., et al. "Age-based (<65 Vs ≥65 Years) Incidence of Infections and Serious Infections With Tofacitinib Versus Biological DMARDs in Rheumatoid Arthritis Clinical Trials and the US Corrona RA Registry." Ann Rheum Dis 2021.
MLA-referensWinthrop, Kevin L., et al. "Age-based (<65 Vs ≥65 Years) Incidence of Infections and Serious Infections With Tofacitinib Versus Biological DMARDs in Rheumatoid Arthritis Clinical Trials and the US Corrona RA Registry." Ann Rheum Dis 2021.